Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has issued an announcement.
Sumitomo Pharma has unveiled its FY2026–FY2028 growth strategy, “Boost 2028 – Accelerating Strong Sumitomo Pharma,” updating the earlier “Reboot 2027” plan after a V-shaped earnings recovery from a sharp FY2023 downturn. The new plan is anchored on expanding sales of blockbuster drugs ORGOVYX and GEMTESA to more than ¥350 billion by FY2028, maintaining ROE of at least 10%, rebuilding its balance sheet with an equity ratio above 50% and a return to net cash, and allocating over ¥180 billion to R&D, including regenerative medicine and cell therapy.
Operationally, the company will concentrate on maximizing the clinical and commercial value of its key urology and oncology products while accelerating development of two priority oncology compounds, enzomenib and nuvisertib, to form its next-generation earnings base. Sumitomo Pharma will also refine its development strategy around early efficacy readouts in hematological cancers and neurodegenerative disorders, and signals that an early resumption of dividends is a goal as financial targets under Boost 2028 are met, underscoring a renewed focus on both growth and shareholder returns.
The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2840.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company focused on prescription drugs, including oncology and urology therapies, as well as regenerative medicine and cell therapy. The company targets global markets with flagship products such as ORGOVYX and GEMTESA while building a pipeline in hematological malignancies and neurodegenerative diseases.
YTD Price Performance: 8.89%
Average Trading Volume: 11,062,550
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen1002.8B
Learn more about 4506 stock on TipRanks’ Stock Analysis page.